	US 12,274,738 B2
	FX activation process and its use in the preparation of a FXa composition
Juergen Roland Roemisch, Gramatneusiedl (AT); Katharina Pock, Vienna (AT); Petra Schulz, Vienna (AT); Silvio Wuschko, Vienna (AT); Michael Andesner, Vienna (AT); and Andrej Muranyi, Vienna (AT)
Assigned to OCTAPHARMA AG, Lachen (CH)
Appl. No. 17/257,705
Filed by OCTAPHARMA AG, Lachen (CH)
PCT Filed Jul. 8, 2019, PCT No. PCT/EP2019/068293 § 371(c)(1), (2) Date Jan. 4, 2021, PCT Pub. No. WO2020/008079, PCT Pub. Date Jan. 9, 2020.
Claims priority of application No. 18182242 (EP), filed on Jul. 6, 2018; and application No. 19153624 (EP), filed on Jan. 24, 2019.
Prior Publication US 2021/0290738 A1, Sep. 23, 2021
Int. Cl. A61K 38/36 (2006.01); A61K 38/48 (2006.01); C07K 1/36 (2006.01); C07K 1/18 (2006.01); C07K 1/22 (2006.01)

CPC A61K 38/4846 (2013.01) [A61K 38/4833 (2013.01); C07K 1/36 (2013.01); C07K 1/18 (2013.01); C07K 1/22 (2013.01); C12Y 304/21005 (2013.01); C12Y 304/21006 (2013.01)]

20 Claims

1. A process for activating Coagulation Factor X (FX) to activated Coagulation Factor X (FXa), wherein the process is performed in vitro and comprises the following steps:

a. providing a composition containing FX and FII; and

b. contacting said composition with phosphatidylserine (PS) and calcium to form an activation composition; and

c. incubating the activation composition to allow a conversion from FX to FXa, wherein the yield of conversion from FX to FXa is in the range of 20%-100%, and

wherein before, during and after incubation no proteinaceous activator is added to the composition(s).